Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT)

Ken Gordon ,M Boehnlein,Andrew Blauvelt ,C Arendt ,Richard B Warren ,A.b Gottlieb ,D Thaçi ,Y Poulin ,F Brock ,Karin Reich

doi:10.25251/skin.4.supp.81

Abstract

Abstract not available.

Highlights

We report the long-term clinical responses for patients with PSO who received open-label treatment with Certolizumab pegol (CZP) dosed at 400 mg every two weeks (Q2W) for up to 128 weeks
Data were pooled from three phase 3 trials in adults with PSO: CIMPASI-1 (NCT02326298), CIMPASI-2 (NCT02326272), and CIMPACT (NCT02346240)
Patients with moderate to severe plaque psoriasis were treated with certolizumab pegol dosed at 400 mg every two weeks for up to 128 weeks

Summary

Introduction

In phase 3 trials, patients with moderate to severe PSO have demonstrated a durable response to CZP over one year (48 weeks) of double-blinded treatment.4,5 We report the long-term clinical responses for patients with PSO who received open-label treatment with CZP dosed at 400 mg every two weeks (Q2W) for up to 128 weeks. At Week 0, patients were randomized to receive CZP 200 mg Q2W (400 mg loading dose at Weeks 0/2/4), CZP 400 mg Q2W, etanercept (CIMPACT only), or placebo.

Objectives

Results

Conclusion